Verma Parul, Chandra Usha, Shukla Prakriti, Verma Shailendra P, Suvirya Swastika
Department of Dermatology, Venereology and Leprosy, King George's Medical University, Lucknow, IND.
Department of Dermatology, Venereology and Leprosy, Lala Lajpat Rai Medical College, Meerut, IND.
Cureus. 2022 Apr 18;14(4):e24228. doi: 10.7759/cureus.24228. eCollection 2022 Apr.
Azacitidine is a hypomethylating agent used for the treatment of patients with myelodysplastic syndrome (MDS). It has been approved by the Food and Drug Administration (FDA) and the European Medicines Agency for the treatment of MDS and is also indicated for the treatment of acute myeloid leukemia (AML). Injection site erythema, ecchymosis, and petechiae are some of the common cutaneous adverse reactions associated with azacitidine. This article describes a rare adverse cutaneous drug reaction with azacitidine in the form of a reticular generalized skin rash in a 28-year-old female with AML.
阿扎胞苷是一种用于治疗骨髓增生异常综合征（MDS）患者的去甲基化药物。它已获得美国食品药品监督管理局（FDA）和欧洲药品管理局批准用于治疗MDS，也被用于治疗急性髓系白血病（AML）。注射部位红斑、瘀斑和瘀点是与阿扎胞苷相关的一些常见皮肤不良反应。本文描述了一名28岁AML女性患者出现的罕见的阿扎胞苷所致皮肤药物不良反应，表现为全身性网状皮疹。
